ZK 756326

ZK 756326 inhibits the binding of the CCR8 ligand I-309 (CCL1), with an IC₅₀ value of 1.8 μM. ZK 756326 is a full agonist of CCR8, dose-responsively eliciting an increase in intracellular calcium and cross-desensitizing the response of the receptor to CCL1. ZK 756326 stimulates extracellular acidification in cells expressing human CCR8. Binding competition assays are performed on a series of other G-protein-coupled receptors to determine whether the interaction of ZK 756326 is specific for CCR8. In these assays, ZK 756326 is tested at 50 μM for inhibition of radiolabeled ligand binding. At this concentration, ZK 756326 shows >28 fold specificity for CCR8 compared with 26 other GPCRs, all with IC₅₀ values of >50 μM. There is less selectivity when ZK 756326 is tested against the serotonergic receptors 5-HT_1A, 5-HT_2B, 5-HT_2C, 5-HT_5A, 5-HT₆, and the adrenergic receptor α2A, in which IC₅₀ values of 5.4, 4,4, 34.8, 16, 5.9, and <20 μM (at 20 μM 65% inhibition), respectively, are observed. The compound is unlikely to be an agonist on these biogenic amine receptors, because when tested at concentrations up to 10 μM on a representative receptor, 5-HT_1A, it shows no agonist activity in a GTPγS binding assay^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.